» Articles » PMID: 27618837

Wnt Signalling Modulates Transcribed-ultraconserved Regions in Hepatobiliary Cancers

Abstract

Objective: Transcribed-ultraconserved regions (T-UCR) are long non-coding RNAs which are conserved across species and are involved in carcinogenesis. We studied T-UCRs downstream of the Wnt/β-catenin pathway in liver cancer.

Design: Hypomorphic Apc mice () and thiocetamide (TAA)-treated rats developed Wnt/β-catenin dependent hepatocarcinoma (HCC) and cholangiocarcinoma (CCA), respectively. T-UCR expression was assessed by microarray, real-time PCR and in situ hybridisation.

Results: Overexpression of the T-UCR uc.158- could differentiate Wnt/β-catenin dependent HCC from normal liver and from β-catenin negative diethylnitrosamine (DEN)-induced HCC. uc.158- was overexpressed in human HepG2 versus Huh7 cells in line with activation of the Wnt pathway. In vitro modulation of β-catenin altered uc.158- expression in human malignant hepatocytes. uc.158- expression was increased in -mutated human HCCs compared with non-mutated human HCCs, and in human HCC with nuclear localisation of β-catenin. uc.158- was increased in TAA rat CCA and reduced after treatment with Wnt/β-catenin inhibitors. uc.158- expression was negative in human normal liver and biliary epithelia, while it was increased in human CCA in two different cohorts. Locked nucleic acid-mediated inhibition of uc.158- reduced anchorage cell growth, 3D-spheroid formation and spheroid-based cell migration, and increased apoptosis in HepG2 and SW1 cells. miR-193b was predicted to have binding sites within the uc.158- sequence. Modulation of uc.158- changed miR-193b expression in human malignant hepatocytes. Co-transfection of uc.158- inhibitor and anti-miR-193b rescued the effect of uc.158- inhibition on cell viability.

Conclusions: We showed that uc.158- is activated by the Wnt pathway in liver cancers and drives their growth. Thus, it may represent a promising target for the development of novel therapeutics.

Citing Articles

KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk.

Jiang Y, Liao C, Lai J, Peng Y, Chen Q, Zheng X Sci Rep. 2025; 15(1):6951.

PMID: 40011455 PMC: 11865440. DOI: 10.1038/s41598-024-84129-1.


Hepatic factor MANF drives hepatocytes reprogramming by detaining cytosolic CK19 in intrahepatic cholangiocarcinoma.

Mei Q, Zhang Y, Li H, Ma W, Huang W, Wu Z Cell Death Differ. 2025; .

PMID: 39972058 DOI: 10.1038/s41418-025-01460-4.


State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.

Giron-Michel J, Padelli M, Oberlin E, Guenou H, Duclos-Vallee J BioDrugs. 2025; 39(2):237-260.

PMID: 39826071 PMC: 11906529. DOI: 10.1007/s40259-024-00702-0.


Sulfation of chondroitin and bile acids converges to antagonize Wnt/-catenin signaling and inhibit APC deficiency-induced gut tumorigenesis.

Xu P, Xi Y, Kim J, Zhu J, Zhang M, Xu M Acta Pharm Sin B. 2024; 14(3):1241-1256.

PMID: 38487006 PMC: 10935170. DOI: 10.1016/j.apsb.2023.12.006.


Potential of lncRNAs to regulate cuproptosis in hepatocellular carcinoma: Establishment and validation of a novel risk model.

He J, Li W, Zhao W, Shen H, Chang Y, Liu B Heliyon. 2024; 10(2):e24453.

PMID: 38312553 PMC: 10835266. DOI: 10.1016/j.heliyon.2024.e24453.


References
1.
Leung W, He M, Chan A, Law P, Wong N . Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett. 2015; 362(1):97-105. DOI: 10.1016/j.canlet.2015.03.023. View

2.
Braconi C, Patel T . Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets. 2012; 12(9):1073-80. PMC: 3916140. View

3.
Fassan M, DallOlmo L, Galasso M, Braconi C, Pizzi M, Realdon S . Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget. 2014; 5(16):7162-71. PMC: 4196192. DOI: 10.18632/oncotarget.2249. View

4.
Boulter L, Guest R, Kendall T, Wilson D, Wojtacha D, Robson A . WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest. 2015; 125(3):1269-85. PMC: 4362247. DOI: 10.1172/JCI76452. View

5.
Liz J, Esteller M . lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2015; 1859(1):169-76. DOI: 10.1016/j.bbagrm.2015.06.015. View